Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02761330
Other study ID # 201512110
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date September 11, 2019

Study information

Verified date June 2021
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is geared toward characterizing the recovery of brain activity and cognitive function following treatments of electroconvulsive therapy and ketamine general anesthesia.


Description:

Seizures are often associated with loss of consciousness, possibly through effects on sub-cortical arousal systems, disruption of cortical-subcortical interactions, and ultimately through depressed neocortical function. Furthermore, people are often confused in the post-ictal state even when consciousness returns after a seizure. Disrupted cognitive function during the postictal phase has not been fully characterized but presents short and long-term implications. Many experience an acute disorder of attention, consciousness, and cognition, referred to as delirium. Memory deficits are also common. The neurobiology for these phenomena are incomplete and challenging to test, as seizures are typically sporadic and vary in intensity and character. In contrast, the setting of electroconvulsive therapy (ECT) provides the opportunity to study the reconstitution of consciousness and cognition following seizures in an elective and predictable context. There is no standard agent used to induce general anesthesia during ECT. Ketamine is receiving greater attention as an infusion for treating depression and for its potential benefits on improving ECT efficacy and expediting cognitive recovery. Further data are needed to determine whether ketamine may improve recovery of cognitive function relative to etomidate, a commonly used anesthetic for general anesthesia during ECT. The investigators will evaluate the cognition function and electroencephalographic patterns that accompany the recovery from ECT and general anesthesia. Twenty patients with refractory depression will be randomized in this interventional single-blinded randomized crossover trial. Each patient will complete seven study visits. The first visit will be conducted during the dose-charge titration ECT treatment with etomidate anesthesia. After this session, patients will be randomized to three sessions each week for two weeks (six treatments total). Over the first week patients will be randomized in order for three treatment arms: (1) etomidate general anesthesia and ECT, (2) ketamine general anesthesia and ECT, and (3) ketamine alone. Patients will be blinded to the treatment arm for each session. Baseline and post-treatment measurements of cognition and ECT will be acquired on each of the six treatment sessions. Patients that agree will have a MRI.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date September 11, 2019
Est. primary completion date September 11, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Treatment resistant depression requiring outpatient ECT - Planned right unilateral ECT stimulation - English speaking - Able to provide written informed consent Exclusion Criteria: - Known brain lesion or neurological illness that causes cognitive impairment - Schizophrenia - Schizoaffective disorder - Blindness or deafness or motor impediments that may impair performance for cognitive testing battery - Inadequate ECT seizure duration with etomidate

Study Design


Intervention

Drug:
Ketamine
Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
Procedure:
Electroconvulsive Therapy
Dose of the ECT charge will be determined during titration session prior to randomization.

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine James S McDonnell Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Cognitive Function During Recovery: Rate of Recovery A cognitive test battery was administered at 0, 30, 60, 90, and 120 minutes following return of consciousness after general anesthesia on each treatment day (1-6). The data from each treatment day (1-6) were averaged for analyses.
Cognition Test Battery:
Psychomotor Vigilance Task (PVT)
Digital Symbol Substitution Task (DSST)
Motor Praxis Task (MP)
Visual Object Learning Task (VOLT)
Abstract Matching (AM)
Rate of Recovery for this measure is defined as the time (in inverse hours) for participants to return to their baseline performance for each task.
0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.
Primary Change in Cognitive Function During Recovery: Initial Decrement A cognitive test battery was administered at 0, 30, 60, 90, and 120 minutes following return of consciousness after general anesthesia on each treatment day (1-6). The data from each treatment day (1-6) were averaged for analyses.
Cognition Test Battery:
Psychomotor Vigilance Task (PVT)
Digital Symbol Substitution Task (DSST)
Motor Praxis Task (MP)
Visual Object Learning Task (VOLT)
Abstract Matching (AM)
Initial Decrement for this measure is defined as the difference between response times (in seconds) at baseline and t=0 for each task.
0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.
Secondary Delirium Incidence and Severity Assessed using 3D Confusion Assessment Method (CAM).
The groups/arms for this outcome are separated by anesthetic regimen; however, due to the crossover design of this study all participants are included in analyses for each group.
Immediately following return of consciousness (t=0) during treatment days 1-6.
Secondary Suicidality The groups/arms for this outcome are combined as a whole-group analysis due to the crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. All participants included in analyses completed all treatments, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in suicidality from baseline to treatment 6 based on the Scale of Suicide Ideation.
The measure completed was the Scale of Suicide Ideation. For this study, participants completed the following questions of the questionnaire:
wish to live (0 Moderate to Strong, 1 Weak, 2 None)
wish to die (0 None, 1 Weak, 2 Moderate to Strong)
The total scores range from 0-4. Lower scores indicate high suicide ideation, and high scores indicate low suicide ideation.
assessed at baseline on treatment days 1-6.
Secondary ECT Seizure Duration Duration (in seconds) of seizure induced by ECT treatment up to days 1-6
Secondary ECT Electrical Dose The electrical dose necessary for seizure induction is determined during a dose-charge titration session prior to participant randomization and session 1. These results report the average electrical dose across all participants for the first treatment session during Treatment Week 1.
The range for these data is 0 - 100% electrical charge.
First ECT treatment session during Treatment Week 1
Secondary Subjective Assessment of Whether ECT Was Performed, Determined by Asking the Patient. To assess patient blinding of treatment performed, the patient will be asked: "Based on how you feel, did you have ECT today?"
Results indicate participants correctly answering the subjective assessment.
Assessed at 120 minutes after return of responsiveness on treatment days 1-6
Secondary Change in Mood Assessed Using the Mood Self-Assessment Manikin Mood Self-Assessment Manikin (SAM) Scale: 1 (very unpleasant) - 9 (very pleasant).
The groups/arms for this outcome are combined as a whole-group analysis due to the Crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. Further, any statistical analyses would be underpowered due to low participant numbers in each arm. Thus, the results are combined and reported as a whole group analysis. All participants included in analyses completed all treatments included in the study, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in mood from baseline to treatment 6 based on the SAM. Additionally, data collected at baseline are not dependent on the study group/arm.
baseline and 120 minutes after return of responsiveness, assessed on treatment days 1-6
Secondary Average Change in Mood Based on the Depression PROMIS-CAT PROMIS-CAT (Patient Reported Outcomes Measurement Information System-Computer Adaptive Testing) for depression
The groups/arms for this outcome are combined as a whole-group analysis due to the Crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. Further, any statistical analyses would be underpowered due to low participant numbers in each arm. Thus, the results are combined and reported as a whole group analysis. All participants included in analyses completed all treatments included in the study, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in mood from baseline to treatment 6 based on the PROMIS-CAT. Additionally, data collected at baseline are not dependent on the study group/arm.
baseline and 120 minutes after return of responsiveness, assessed on treatment days 1-6
Secondary Change in Delta Band (0.5-4 Hz) Relative Power in the Scale EEG During Recovery High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the delta band over the sum of total power between 0.5 - 70Hz. baseline, post-ECT from 0-120 minutes
Secondary Change in Theta Band (4-8 Hz) Relative Power in the Scalp EEG During Recovery High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the theta band over the sum of total power between 0.5 - 70Hz. baseline, post-ECT from 0-120 minutes
Secondary Change in Alpha Band (8-13 Hz) Power in the Scalp EEG During Recovery High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the alpha band over the sum of total power between 0.5 - 70Hz. baseline, post-ECT from 0-120 minutes
Secondary Change in Beta Band (13-20 Hz) Relative Power in the Scalp EEG During Recovery High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the beta band over the sum of total power between 0.5 - 70Hz. baseline, post-ECT from 0-120 minutes
Secondary Change in Anterior-Posterior Functional Connectivity in the Scalp During Recovery High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the coherence measure, which is used for tracking changes in anterior-posterior functional connectivity.
Coherence is a measure of synchronization between two signals which is used to measure anterior-posterior functional connectivity. Coherence is a unitless measure between 0 and 1. High coherence between time-series of two neural populations reflects higher efficiency in communication between those populations and therefore stronger functional connectivity.
baseline, post-ECT from 0-120 minutes
Secondary Change in Anterior-Posterior Phase-lag in the Scalp EEG During Recovery High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Phase-lag was assessed using the Phase-Lag Index (PLI), a measure ranging from 0 - 1. A consistent phase-lag between two tim-series results in a PLI of 1. A time-series without coupling results in a PLI near or equaling 0. Results show the difference in anterior-posterior PLI between baseline and post-ECT. baseline, post-ECT from 0 -120 minutes
Secondary Change in EEG Entropy in the Scalp EEG During Recovery High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as permutation entropy (PE) measures in posterior regions, which we are using to track changes in scalp EEG entropy.
Permutation Entropy (PE) is a measure that is used to quantify the complexity of time series signals. It is a unitless measure between 0 and 1. Lower the PE represents a more regular and more deterministic time series while higher PE represents a more complex time series.
baseline, Post-ECT from 0 -120 minutes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A